KYNTRA BIO, INC. Effective Income Tax Rate Reconciliation Gilti Percent
KYNTRA BIO, INC. (KYNB) reported Effective Income Tax Rate Reconciliation Gilti Percent of -107.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent · last filed 2026-03-16
- KYNTRA BIO, INC. effective income tax rate reconciliation gilti percent for fiscal 2025 was -107.60%.
- KYNTRA BIO, INC. effective income tax rate reconciliation gilti percent for fiscal 2024 was -2.10%, a 155.26% decline from fiscal 2023.
- KYNTRA BIO, INC. effective income tax rate reconciliation gilti percent for fiscal 2023 was 3.80%, a 35.71% increase from fiscal 2022.
- KYNTRA BIO, INC. effective income tax rate reconciliation gilti percent for fiscal 2022 was 2.80%, a 600.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation Gilti Percent 12 month | Effective Income Tax Rate Reconciliation Gilti Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -107.60% 10-K · filed 2026-03-16 | |
| 2024-12-31 | -2.10% 10-K · filed 2026-03-16 | 2.10% 10-K · filed 2025-03-17 |
| 2023-12-31 | 3.80% 10-K · filed 2025-03-17 | 4.30% 10-K · filed 2024-02-26 |
| 2022-12-31 | 2.80% 10-K · filed 2024-02-26 | |
| 2021-12-31 | 0.40% 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |